Abstract :Objective To evaluate the clinical effect of compound polymyxin B combined with recombinant human epidermal growth factor in the treatment of infected wounds in burn patients in order to guide clinical diagnosis and treatment.Methods A total of 50 patients with deep second-degree burns who were admitted to the burn department of the hospital from January 2014 to June 2015 were selected as the research subjects and divided into a control group and an observation group according to the random number table method, with 25 cases in each group. The observation group was treated with compound polymyxin B combined with recombinant human epidermal growth factor, and the control group was treated with recombinant human epidermal growth factor. The clinical treatment effects of the two groups were compared, and the data were statistically analyzed using SPSS 17.0 software. Results The growth time of granulation tissue in the observation group was (5.3±1.3) d, which was significantly different from that in the control group (6.9±1.7) d (P<0.05). The scar incidence rate was 12.0% in the observation group and 16.0% in the control group, with no significant difference between the two groups. The wound healing rates at 7, 14, and 21 d in the observation group were 44.0%, 64.0%, and 92.0%, respectively, while those at 16.0%, 32.0%, and 60.0%, respectively, in the control group, with significant differences between the two groups (P<0.05). The wound infection rates at 7, 14, and 21 d in the observation group were 64.0%, 52.0%, and 28.0%, respectively, while those at 88.0%, 80.0%, and 68.0%, respectively, in the control group, with significant differences between the two groups (P<0.05). Conclusion The combined use of compound polymyxin B and recombinant human epidermal growth factor in the treatment of infected wounds in burn patients has the advantages of preventing infection, fast healing, and low scar incidence , and is worthy of clinical promotion.
Liu J, Li WQ, Han YL, Ji G, Jiang H. Analysis of the efficacy of polymyxin B combined with recombinant human epidermal growth factor in the treatment of infected wounds in burn patients[J]. Chinese Journal of Hospital Infection, 2016, 26(04): 886-888.